生物制剂预防重症哮喘患者新发全身性不良结局
该纵向队列研究基于国际重症哮喘注册库(ISAR,16国)和英国Optimum Patient Care研究数据库(OPCRD),纳入42,908例患者,比较生物制剂启动者与非启动者新发口服糖皮质激素(OCS)相关不良结局的风险。结果显示生物制剂启动者任何OCS相关不良结局发生率降低(HR 0.82,95%CI 0.72-0.93;P=0.002),主要由糖尿病、主要心血管事件及焦虑和/或抑郁发生率降低驱动。
要点
- 生物制剂启动者任何OCS相关不良结局风险降低(HR 0.82)。
- 糖尿病、主要心血管事件及焦虑和/或抑郁风险显著降低。
- 白内障、睡眠呼吸暂停及骨质疏松等风险无显著差异。
核心结论
- 生物制剂有助于预防重症哮喘患者新发OCS相关不良结局。
研究设计与样本
- 纵向队列研究,使用ISAR(16国)和OPCRD(英国)汇总数据,共纳入42,908例患者。
- 采用逆概率处理加权提高组间可比性,加权Cox比例风险模型估计风险比(HR),随访至索引日期后5年。
主要发现
- 生物制剂启动者任何OCS相关不良结局发生率低于非启动者(HR 0.82,95%CI 0.72-0.93;P=0.002)。
- 糖尿病发生率降低(HR 0.62,95%CI 0.45-0.87;P=0.006)。
- 主要心血管事件发生率降低(HR 0.65,95%CI 0.44-0.97;P=0.034)。
- 焦虑和/或抑郁发生率降低(HR 0.68,95%CI 0.55-0.85;P=0.001)。
- 新发白内障(HR 0.77,95%CI 0.47-1.25)、睡眠呼吸暂停(HR 0.82,95%CI 0.78-1.41)及其他OCS相关不良结局(如骨质疏松)无显著差异。
关键数值与推荐
- 生物制剂启动者中长期OCS使用者占27.3%,非启动者占4.7%(索引日期前一年内连续每日摄入≥90天)。
- 生物制剂启动者平均泼尼松龙等效日剂量为10.2 mg,非启动者为6.2 mg。
临床怎么用
- 对重症哮喘患者启动生物制剂可能减少新发OCS相关不良结局,尤其是糖尿病、主要心血管事件及焦虑和/或抑郁。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Although clinical trials have documented the oral corticosteroid (OCS)-sparing effect of biologics in patients with severe asthma, little is known about whether this translates to a reduction of new-onset OCS-related adverse outcomes. Objective: To compare the risk of developing new-onset OCS-related adverse outcomes between biologic initiators and noninitiators. Methods: This was a longitudinal cohort study using pooled data from the International Severe Asthma Registry (ISAR; 16 countries) and the Optimum Patient Care Research database (OPCRD; United Kingdom). For biologic initiators, the index date was the date of biologic initiation. For noninitiators, it was the date of enrollment (for ISAR) or a random medical appointment date (for OPCRD). Inverse probability of treatment weighting was used to improve comparability between groups, and weighted Cox proportional hazard models were used to estimate the hazard ratios (HRs) of developing OCS-related adverse outcomes for up to 5 years from the index date. Measurements and Main Results: A total of 42,908 patients were included. Overall, 27.3% and 4.7% of biologic initiators and noninitiators were long-term OCS users (daily intake ⩾90 consecutive days in year before the index date), with a mean prednisolone-equivalent daily dose of 10.2 mg and 6.2 mg, respectively. Compared with noninitiators, biologic initiators had decreased rate of developing any OCS-related adverse outcome (HR [95% confidence interval (CI)]: 0.82 [0.72-0.93]; P = 0.002), primarily driven by reduced rate of developing diabetes (0.62 [0.45-0.87]; P = 0.006), major cardiovascular events (0.65 [0.44-0.97]; P = 0.034), and anxiety and/or depression (0.68 [0.55-0.85]; P = 0.001). There were no significant differences in the rates of new-onset cataract (HR, 0.77 [95% CI, 0.47-1.25]), sleep apnea (HR, 0.82 [95% CI, 0.78-1.41]), or other OCS-related adverse outcomes assessed (e.g., osteoporosis). The results were consistent across both datasets. Conclusions: Our findings highlight the role for biologics in preventing new-onset OCS-related adverse outcomes in patients with severe asthma.
引用
- Sadatsafavi M, Tran TN, Scelo G, et al. Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am J Respir Crit Care Med. 2025. PMID: 40383109. doi:10.1164/rccm.202501-0246OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。